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Background: Cutaneous pemphigoid (bullous pemphigoid) is an autoimmune bullous 41 
disease that typically presents with tense bullae and severe pruritus. However, 42 
bullae may be lacking, a subtype termed nonbullous cutaneous pemphigoid. 43 
Objective: To summarize the reported characteristics of nonbullous cutaneous 44 
pemphigoid. 45 
Methods: The EMBASE and MEDLINE databases were searched using ‘nonbullous 46 
cutaneous pemphigoid’ and various synonyms. Case reports and series describing 47 
nonbullous cutaneous pemphigoid were included. 48 
Results: The search identified 133 articles. After selection 39 articles were included, 49 
presenting 132 cases. Erythematous, urticarial plaques (52.3%) and 50 
papules/nodules (20.5%) were the most reported clinical features. The mean age at 51 
presentation was 74.9 years. Histopathology was commonly nonspecific. Linear 52 
depositions of IgG/C3 along the basement membrane zone were found by direct 53 
immunofluorescence microscopy in 93.2%. Indirect immunofluorescence on salt split 54 
skin was positive in 90.2%. The mean diagnostic delay was 22.6 months. The 55 
minority of patients (9.8%) developed bullae during the reported follow-up.  56 
Limitations: Results are mainly based on case reports/small case series. 57 
Conclusion: Nonbullous cutaneous pemphigoid is an underdiagnosed variant of 58 
pemphigoid that most often does not evolve to bullous lesions, and mimics other 59 
pruritic skin diseases. Greater awareness among physicians is needed to avoid 60 














INTRODUCTION  63 
Cutaneous pemphigoid, also known as bullous pemphigoid (BP), is the most common 64 
autoimmune bullous disease affecting the skin and mucous membranes, with autoantibodies 65 
directed against the 180 kDa BP antigen (BP180) and the 230 kDa BP antigen (BP230) 66 
located in the basement membrane zone (BMZ).1 The disease commonly affects older 67 
patients and is associated with an increased risk of mortality, as well as a significant decline 68 
in quality of life and psychological well-being.2-6  69 
The clinical phenotype of cutaneous pemphigoid is polymorphic. The typical 70 
presentation consists of tense blisters that arise on erythematous, urticarial plaques, and is 71 
accompanied by severe pruritus.1,3 Prior to blister formation pruritus can occur as a 72 
prodrome, with or without primary skin manifestations.7 In contrast to the typical bullous 73 
presentation, various atypical variants of cutaneous pemphigoid have been reported with 74 
terms such as papular pemphigoid, pemphigoid nodularis, pemphigoid vegetans, 75 
erythrodermic pemphigoid, pruritic nonbullous pemphigoid and erythema multiforme-like 76 
pemphigoid.8-11 The nonbullous variant of cutaneous pemphigoid  presents with pruritus and 77 
various nonbullous findings on the skin, such as erythematous patches, urticarial plaques, 78 
papules, nodules, excoriations, eczema, and erythroderma. Moreover, this variant can even 79 
present without primary skin lesions, called ‘pruritus on primary, non-diseased, non-inflamed 80 
skin’ according to the International Clinical Classification of Itch.11,12 Previous articles have 81 
emphasized the need for uniform terminology and discussed the urge for renaming bullous 82 
pemphigoid, since the use of the adjective ‘bullous’ is redundant considering that 83 
‘pemphigoid’ means ‘resembling pemphigus’ and pemphigus is Greek for ‘blister’.8,13-15 84 
Borradori and Joly proposed the term ‘cutaneous pemphigoid’.13 To emphasize the lack of 85 
bullae in the nonbullous disease variant, we proposed to add the adjective nonbullous.14 86 
Hence, the terminology used in this article.  87 
Cohort studies show that at least 20% of all pemphigoid patients do not have blisters 88 
at the time of diagnosis.3,15 Thus, nonbullous cutaneous pemphigoid is not that uncommon or 89 
atypical as may be assumed.16 The bullous and nonbullous cutaneous pemphigoid 90 
phenotypes are immunologically indistinguishable. The diagnosis is usually based on the 91 













(DIF) microscopy, and immunoserology.15 One of the main obstacles currently is the lack of 93 
consensus on the minimal diagnostic criteria of cutaneous pemphigoid.8,13,14,16,17 The 94 
absence of blistering in nonbullous cutaneous pemphigoid can make the recognition of this 95 
disease difficult for clinicians and may result in a delay of diagnosis.18,19 96 
The aim of our study is to characterize and define nonbullous cutaneous pemphigoid 97 
by systematic review, which has not been performed before. Our study lists reported clinical 98 
presentations, histopathological findings, laboratory findings, and prognosis regarding 99 













MATERIALS AND METHODS 101 
Search strategy 102 
The literature search for this review was conducted in the EMBASE and MEDLINE 103 
databases on the 4th of November 2016. Various terms and synonyms for ‘nonbullous 104 
cutaneous pemphigoid’ were used (supplement 1). There were no limitations on article type. 105 
After the selection procedure the references of all included articles were checked for missing 106 
articles.  107 
Selection of articles 108 
Language was limited to Dutch, German or English. Independent screening of the titles and 109 
abstracts was carried out by AL and JM. Discrepancies between the researchers were 110 
resolved through discussion. All articles reporting on one or multiple cases of nonbullous 111 
cutaneous pemphigoid were included. Nonbullous cutaneous pemphigoid was defined as all 112 
symptomatic cases with a nonbullous phenotype, that lacked a previous history of bullae, 113 
and fulfill the following diagnostic criteria of cutaneous pemphigoid: a positive DIF with linear 114 
IgG and/or C3c along the BMZ and/or positive indirect immunofluorescence (IIF), in 115 
combination with compatible clinical presentation, histopathological findings, or other 116 
immunoserological tests. If the full text was not available online it was ordered at the national 117 
library. Poster abstracts were only included if sufficient individual patient data was presented.  118 
Data collection 119 
The following variables were gathered: age at diagnosis, gender, duration of symptoms 120 
before the diagnosis was made, clinical presentation, results of diagnostic tests, 121 
histopathological findings, total follow-up time and whether blisters developed during follow-122 














Systematic search results 125 
A total of 39 articles presenting a total of 132 cases of nonbullous cutaneous pemphigoid 126 
were identified (supplement 2). Figure 1 displays the selection procedure. The first case of 127 
nonbullous cutaneous pemphigoid was reported in 1983 by Barker et al.20 The largest case 128 
series was from Lamb et al.21, who described the clinical presentation of 53 patients 129 
diagnosed with ‘prodromal bullous pemphigoid’. This large case series did not present 130 
individual patient characteristics concerning age, gender, duration of symptoms, 131 
histopathological findings and total duration of follow-up. However, we were able to include 132 
the reported clinical presentation and the number of cases that developed blisters during 133 
follow-up. 134 
Clinical presentation 135 
Table 1 shows the demographics of the reported patients with nonbullous cutaneous 136 
pemphigoid. The mean age at presentation was 74.9 years. The reported efflorescences and 137 
configurations of skin lesions seen at dermatological examination are displayed in table 2.  138 
Table 3 presents the location of skin lesions, reported in 64 of the 132 cases.  139 
Histopathology 140 
The histopathological findings were described in 53 individual cases. A perivascular infiltrate 141 
was seen most frequently (n=32; 60.4%), which is a non-specific finding. Additionally, non-142 
specific findings not further specified were reported in 14 cases (26.4%). Eosinophils were 143 
present in the biopsies of 25 cases (47.2%) and neutrophils in 7 cases (13.2%). Spongiosis 144 
without eosinophils was reported in 10 cases (18.9%), while eosinophilic spongiosis was 145 
seen in 4 patients (7.5%). The presence of dermal edema was reported in 8 cases (15.1%). 146 
The presence of a microscopic subepidermal split was reported in 8 patients (15.1%).  147 
Laboratory findings 148 
Table 4 shows the reported laboratory findings of patients with nonbullous cutaneous 149 
pemphigoid. In all cases DIF microscopy was performed. In cases with a negative DIF result, 150 













targeted antigen. IIF was the most commonly performed  immunoserological test (55 cases). 152 
The substrate used in IIF was not specified in 15 cases. In the other cases monkey 153 
esophagus (n=27) or human skin (n=13) were used as substrate. The BP230 ELISA was the 154 
least performed immunoserological test (n=19). Additionally in four cases 155 
immunoprecipitation was used to identify antigens, resulting in a positive reaction to both 156 
BP180 and BP230 in one case and only a positive reaction to BP230 in three cases. 157 














This systematic review summarizes the reported characteristics of nonbullous cutaneous 160 
pemphigoid. The most frequently reported skin efflorescences were erythematous, urticarial 161 
plaques (52.3%). Pruritus was reported in 100% of the cases. Overall, the duration between 162 
the start of symptoms and the correct diagnosis was very long (mean 22.6 months). Only 13 163 
patients (9.8%) developed bullae during the reported follow-up, thus were actually prodromal 164 
to the bullous phase of cutaneous pemphigoid. However, in the majority of the cases 165 
(90.2%) bullae never occurred. The findings of this review show that although the clinical 166 
presentation of nonbullous cutaneous pemphigoid is various, pruritus at high age may be a 167 
clinical clue.  168 
Our study identified several similarities in clinical characteristics of nonbullous and 169 
bullous cutaneous pemphigoid. Both present at older age (mean 74.9 versus 77.2 – 82.6 170 
years).4-6 Furthermore, in both variants lesions are most frequently located on the trunk and 171 
extremities.18,22 Most of the skin efflorescences reported in nonbullous cutaneous 172 
pemphigoid cases can also be found in patients with cutaneous pemphigoid with bullae.1,15 173 
On the other hand, mucosal involvement was rarely reported in nonbullous cutaneous 174 
pemphigoid, while reported in 10-30% of patients with cutaneous pemphigoid.3,15,22 In 14 175 
cases the configurations of the skin lesions were reported to be annular, gyrate, figurate or 176 
herpetiform.21,23-30 Two of these patients presented with targetoid lesions.21,25 We also found 177 
three case reports that were possibly drug induced due to nifedipine, lisinopril and the 178 
combination of allopurinol plus colchicine.25,31,32 Nifedipine and lisinopril were previously 179 
associated with cutaneous pemphigoid, however it is not shown that these drugs actually 180 
cause a higher risk to develop cutaneous pemphigoid.33,34 Studies did show that the use of 181 
spironolactone and neuroleptics are independent risk factors for the development of 182 
cutaneous pemphigoid.35,36 183 
 The reported histopathological findings in nonbullous cutaneous pemphigoid differ from 184 
cutaneous pemphigoid with typical bullae in several aspects. Histopathological findings were 185 
commonly nonspecific in nonbullous cutaneous pemphigoid and resembled eczema or 186 
prurigo nodularis. While cutaneous pemphigoid with bullae is usually characterized by the 187 













with nonbullous cutaneous pemphigoid histopathological findings only described eosinophilic 189 
spongiosis in 7.5% and a subepidermal split in 15.1%.1,37 These findings emphasize the 190 
need to always perform DIF microscopy and immunoserology in addition to histopathology in 191 
patients in which nonbullous cutaneous pemphigoid is suspected. In nonbullous cutaneous 192 
pemphigoid DIF microscopy was the most reported positive diagnostic test (positive in 193 
93.2%) followed by IIF on salt-split skin (SSS) (90.2%). Both DIF microscopy and IIF on SSS 194 
have a high specificity (98% and 100% respectively).38 Yet, the reported percentage of 195 
positive findings in DIF microscopy in nonbullous cutaneous pemphigoid might be an 196 
overestimation, since this test is regarded as the reference standard for diagnosis of 197 
pemphigoid and commonly the only performed immunopathological test.39 Consequently the 198 
diagnosis of pemphigoid might be rejected when DIF microscopy is negative and 199 
immunoserological analysis might not have been performed.  200 
 The mean duration of symptoms of nonbullous cutaneous pemphigoid until the correct 201 
diagnosis of pemphigoid was 22.6 months. These results seem to be consistent with other 202 
research that also found long diagnostic delays in pemphigoid cases that lack bullae. 203 
Previously, we reported a mean delay in diagnosis of 33.6 months in 15 patients with 204 
nonbullous cutaneous pemphigoid.14 The studies of Zhang et al. and Sun et al. reported 205 
misdiagnosis with eczema, nodular prurigo or other dermatologic diseases in all pemphigoid 206 
patients that initially presented without bullae, 181 and 24 patients respectively.18,40 In both 207 
studies the correct diagnosis was made when bullae appeared, which was after a mean 208 
duration of 15.9 months and 20.75 months (range 1 month to 19 years). Although these 209 
studies only identified misdiagnosis in prodromal cutaneous pemphigoid patients, they also 210 
illustrate the importance of more awareness and better knowledge regarding the 211 
characteristics of nonbullous cutaneous pemphigoid. In contrast, Della Torre et al. did not 212 
find a significant difference in delay of diagnosis between patients with bullous (n=97) and 213 
nonbullous (n=20) cutaneous pemphigoid in their cohort.3 Whether early recognition and 214 
immunosuppressive treatment of nonbullous cutaneous pemphigoid can prevent later blister 215 
development is unknown.  216 
 A much debated question is whether patients diagnosed with nonbullous cutaneous 217 













majority of nonbullous cutaneous pemphigoid patients did not develop blisters during follow-219 
up supports the hypothesis that nonbullous cutaneous pemphigoid is not a prodromal stage 220 
but merely a variant within the clinical spectrum of pemphigoid diseases. We can conclude 221 
that ‘prodromal pemphigoid’ is an incorrect term and that there is a need for consensus 222 
regarding the terminology to describe this disease variant. We strongly argue for insertion of 223 
the term nonbullous cutaneous pemphigoid in the EMTREE. 224 
During our literature search we identified a number of other subepidermal autoimmune 225 
blistering diseases with nonbullous clinical presentations: nonbullous epidermolysis bullosa 226 
acquisita41, nonbullous linear IgA dermatosis42 and nonbullous pemphigoid gestationis43.  227 
Furthermore we came across reports of cutaneous pemphigoid patients that first presented 228 
with bullae and later experienced a nonbullous flare-up of the disease.44-49 These cases 229 
strengthen the idea that nonbullous cutaneous pemphigoid should be seen as a disease 230 
variant within the spectrum of pemphigoid diseases. Previous publications reported a higher 231 
prevalence of BP-specific autoantibodies in older dermatology patients (>75 years) without 232 
blisters, healthy blood donors, and elderly individuals with pruritus.50-52 How these patients fit 233 
the pemphigoid spectrum has not been clarified.  234 
Our systematic review provides insight on reported literature on nonbullous cutaneous 235 
pemphigoid so far. A limitation of this review is that the results are mainly based on single 236 
case reports and small case series. Consequently missing values were present in the 237 
summarized data. Moreover, in some publications the clinical picture was described very 238 
briefly. A second limitation of this review is the risk of reporting bias, since cases with 239 
unusual atypical presentations are more likely to be reported in the literature. Furthermore, 240 
the finding that the majority (90.2%) of nonbullous cutaneous pemphigoid patients did not 241 
develop blisters during the reported follow-up (mean 19.8 months;range 0-72) might be 242 
slightly biased by selection, since we excluded cases of cutaneous pemphigoid that were 243 
diagnosed after bullae appeared, even though authors retrospectively described pruritic 244 
symptoms prior to blistering. However, it is uncertain whether these symptoms prior to 245 
diagnosis were caused by pemphigoid, or by other pruritic dermatoses, such as prurigo 246 
nodularis or eczema. This study therefore highlights the importance of larger observational 247 













 Another interesting focus for future research is why patients with nonbullous 249 
cutaneous pemphigoid do not develop bullae. Several factors have been suggested to 250 
influence blister formation, such as autoantibody titers,53 the antigens or epitopes targeted by 251 
autoantibodies,22,54 complement involvement,55,56 and eosinophils.57 More knowledge of the 252 
underlying pathophysiology of this subtype of pemphigoid might lead to more awareness and 253 
less delay in diagnosis of nonbullous cutaneous pemphigoid. 254 
In conclusion, our review showed that the reported clinical presentation of nonbullous 255 
cutaneous pemphigoid can be heterogeneous. The reported long duration of symptoms until 256 
correct diagnosis (mean 22.6 months) illustrates that nonbullous cutaneous pemphigoid can 257 
be difficult to recognize for clinicians. Pruritus in elderly is a common denominator in patients 258 
with nonbullous cutaneous pemphigoid and in our opinion the most important clue for 259 
recognition. Clinicians should therefore perform DIF on a skin biopsy and immunoserological 260 
analysis on a blood sample in elderly with unexplained or refractory chronic pruritus and 261 
erythematous, urticarial papules and plaques. Further study is needed to evaluate the 262 























ABBREVIATION LIST 274 
BP   bullous pemphigoid  275 
BP180 180 kDa BP antigen  276 
BP230 230 kDa BP antigen  277 
BMZ  basement membrane zone 278 
DIF  direct immunofluorescence 279 
IIF   indirect immunofluorescence 280 
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Table 1 486 
Table 1. Demographics of the reported cases of nonbullous cutaneous pemphigoid  487 
Demographic outcome measurements   Reported in 
no. of cases  
Mean age at presentation, in years  74.9  SD 11.8; range 39-95 78 
Male cases, proportion  33 (42.3%)  78 
Cases experiencing pruritus, proportion 77 (100%)  77 
Cases with reported mucosal lesions, proportion  1* (7.1%)  14 
Mean duration of symptoms before diagnosis, in 
months 
22.6  SD 39.1; range 0-240 50 
Cases with blister development after diagnosis, 
proportion 
13 (9.8%)  132 
       - Mean duration of symptoms until blisters    
       occurred, in months 
15.9 SD 8.4; range 7.5-27 5 
       - Mean duration from diagnosis till blisters    
       occurred, in months  
9.6  SD 8.6; range 1-21 7 
Mean total follow-up, in months  19.6  SD 18.6; range 0-72 46 
SD, standard deviation; * Ulceration in the mouth that healed without scarring, other mucosal areas were spared 32 488 
 489 
Table 2 490 
Table 2. Skin findings and configurations reported in cases of nonbullous 
cutaneous pemphigoid  
Skin findings reported No. of cases (%)  
Erythematous, urticarial papules and plaques 69 (52.3%) 
Papules/nodules 27 (20.5%) 
Eczematous lesions  16 (12.1%)  
No primary lesions reported¶ 6 (4.5%)  
Dermatitis herpetiformis-like lesions 5 (3.8%) 
Ulcerations 3 (2.3%) 
Erythroderma 3 (2.3%)  
Other:    
     Scarring alopecia 1 (0.8%) 
     Vegetations 1 (0.8%) 
     Solitary macule 1 (0.8%) 
Excoriations 30 (22.7%) 
Configuration reported 
Annular configuration*  8 (6.1%)  
Figurated configuration 2 (1.5%) 
Gyrated configuration 1 (0.8%) 
The clinical presentation was reported in all 132 cases.  491 
¶ all 6 cases presented with secondary lesions in the form of excoriations 492 
* two cases presented with erythema mulitformis-like lesions 493 
 494 
Table 3 495 
Table 3. Reported localization of skin lesions  in  496 
nonbullous cutaneous pemphigoid 497 
Localization 
reported 
No. of cases (%) 
Extremities 43 (67.2%) 
Trunk 42 (65.6%) 
Generalized  14 (21.9%) 
Head and/or neck 7 (10.9%) 
Scalp 6 (9.4%) 
Hands and/or feet 5 (7.8%) 
















Table 4 502 
Table 4. Reported laboratory findings   
 
No. of cases with 
positive test results (%) 
Reported in no. 
cases 
DIF microscopy, linear IgG and/or C3c 
depositions along the BMZ 
123 (93.2%) 132 
IIF* IgG 42 (76.4%) 55 
IIF on salt split skin, IgG, epidermal 
binding  
46 (90.2%) 51 
Nc16a ELISA,  IgG 15 (57.7%) 26 
BP230 ELISA, IgG 10 (52.6%) 19 
Immunoblot BP180, IgG 11 (32.4%) 34 
Immunoblot BP230, IgG 20 (55.6%) 36 
DIF, direct immunofluorescence; IgG, immunoglobulin G; BMZ, basement membrane zone; IIF, indirect 503 
immunofluorescence; Nc16a, non-collagen 16a; ELISA, enzyme linked immunosorbent assay.   504 















SUPPLEMENTARY MATERIAL 508 
Supplement 1 509 
Keywords used in the systematic search (performed in EMBASE & MEDLINE)  510 
('non*bullous' AND 'pemphigoid') OR ‘non*bullous pemphigoid' OR non*bullous bullous 511 
pemphigoid’ OR ‘non*bullous BP’ OR 'pruritic pemphigoid' OR 'pruritic non*bullous 512 
pemphigoid' OR 'pemphigoid nodularis' OR 'nodular pemphigoid' OR 'prurigo nodularis-like 513 
pemphigoid' OR  'papular pemphigoid' OR 'prodromal BP' OR 'prodromal bullous 514 
pemphigoid' OR 'prodromal pemphigoid' OR 'prodrome of bullous pemphigoid' OR  ‘non 515 
bullous variant' NEAR/10 'pemphigoid' OR 'nonbullous variant' NEAR/10 'pemphigoid' OR 516 
'bullous pemphigoid mimicking' OR '-like bullous pemphigoid' OR 'erythrodermic bullous 517 
pemphigoid' OR ('bullous pemphigoid' AND 'without blister*') OR ('bullous pemphigoid'/exp 518 
AND 'without blister*') OR  ('bullous pemphigoid' AND 'without bullae') OR ('bullous 519 
pemphigoid' AND 'without bullous lesions') 520 
 521 
 522 
Supplement 2 523 
List of all included articles presenting cases of nonbullous cutaneous pemphigoid 524 
First author Publication year 
Barker et al.20 1983 
Bingham et al.58  1984 
Amato et al.24 1988 
Borradori et al.59 1990 
Wolf et al.60 1992 
Ross et al.49 1992 
Strohal et al.10  1993 
Bourke et al.45 1994 
Wever et al.61  1995 
Jeong et al.62  1995 
Cliff et al.63  1996 
Kawahara et al.53 1997 
Alonso-Llamazares et al.64  1998 
Alonso-Llamazares et al.65  1998 
Scrivener et al.66 1999 
Ameen et al.32 2000 
Schmidt et al.67  2002 
Powell et al.68 2002 
Goel et al.69 2003 













 525 Tashiro et al.30 2005 
von Felbert et al.71 2005 
Lamb et al.21 2006 
Yesudian et al.72  2009 
Matsudate et al.73  2009 
Axelrod et al.25 2010 
Safa et al.74 2010 
McCourt et al.75 2010 
Geiss Steiner et al.76  2010 
Lehman et al.77 2011 
Patel et al.29 2012 
Bakker et al.11  2013 
Balakirski et al.78 2014 
Liu et al.31  2014 
Kabuto et al.27  2015 
Altman et al.23  2015 
Park et al.28 2015 
Huet et al.79 2016 


























Capsule summary  
 
• What is already known on this topic. 
Cutaneous pemphigoid can present without typical bullae and consequently diagnosis  
can be delayed. 
 
• What this article adds to our knowledge. 
The most frequently reported clinical features in these patients are pruritic, 
erythematous, urticarial papules and plaques.  
• How this information impacts clinical practice and/or changes patient care.  
Clinicians should consider nonbullous cutaneous pemphigoid in older patients with 
refractory pruritus. 
 
